[go: up one dir, main page]

ATE90573T1 - Verfahren zum stabilisieren von menschlichen albuminloesungen und so erhaltene loesung. - Google Patents

Verfahren zum stabilisieren von menschlichen albuminloesungen und so erhaltene loesung.

Info

Publication number
ATE90573T1
ATE90573T1 AT89400947T AT89400947T ATE90573T1 AT E90573 T1 ATE90573 T1 AT E90573T1 AT 89400947 T AT89400947 T AT 89400947T AT 89400947 T AT89400947 T AT 89400947T AT E90573 T1 ATE90573 T1 AT E90573T1
Authority
AT
Austria
Prior art keywords
human albumin
solution obtained
albumin solutions
stabilizing human
tween
Prior art date
Application number
AT89400947T
Other languages
English (en)
Inventor
Michel Grandgeorge
Pierre Fournier
Original Assignee
Pasteur Merieux Serums Vacc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9365304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE90573(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Merieux Serums Vacc filed Critical Pasteur Merieux Serums Vacc
Application granted granted Critical
Publication of ATE90573T1 publication Critical patent/ATE90573T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT89400947T 1988-04-14 1989-04-06 Verfahren zum stabilisieren von menschlichen albuminloesungen und so erhaltene loesung. ATE90573T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8804936A FR2630115B1 (fr) 1988-04-14 1988-04-14 Procede de stabilisation des solutions d'albumine humaine et solution obtenue
EP89400947A EP0341103B2 (de) 1988-04-14 1989-04-06 Verfahren zum Stabilisieren von menschlichen Albuminlösungen und so erhaltene Lösung

Publications (1)

Publication Number Publication Date
ATE90573T1 true ATE90573T1 (de) 1993-07-15

Family

ID=9365304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89400947T ATE90573T1 (de) 1988-04-14 1989-04-06 Verfahren zum stabilisieren von menschlichen albuminloesungen und so erhaltene loesung.

Country Status (9)

Country Link
US (1) US5118794A (de)
EP (1) EP0341103B2 (de)
JP (1) JP2970911B2 (de)
AT (1) ATE90573T1 (de)
AU (1) AU617451B2 (de)
CA (1) CA1339440C (de)
DE (1) DE68907124T3 (de)
ES (1) ES2055120T5 (de)
FR (1) FR2630115B1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US4939176A (en) * 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
DE69329795T2 (de) * 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
AU6653094A (en) * 1992-12-16 1994-07-04 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
EP0682524B1 (de) * 1993-02-02 2001-10-04 XOMA Technology Ltd. Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
JPH07126182A (ja) * 1993-10-27 1995-05-16 Green Cross Corp:The 組換えヒト血清アルブミン製剤の滅菌方法
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US5583114A (en) 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
USRE38827E1 (en) 1994-07-27 2005-10-11 3M Innovative Properties Company Adhesive sealant composition
AT403989B (de) * 1996-09-16 1998-07-27 Immuno Ag Verfahren zur herstellung eines plasmaprotein-hältigen arzneimittels
JPH10251161A (ja) * 1997-03-11 1998-09-22 Green Cross Corp:The 浮腫治療効果増強剤
DE19830914C1 (de) * 1998-07-10 1999-06-24 Centeon Pharma Gmbh Verfahren zur Herstellung einer Proteinlösung
DE19858188A1 (de) * 1998-12-17 2000-07-06 Centeon Pharma Gmbh Verfahren zum Auflösen von Albuminflocken in einer Flüssigkeit sowie Einrichtung zur Durchführung des Verfahrens
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
PT1253932E (pt) * 2000-02-08 2005-07-29 Allergan Inc Composicoes farmaceuticas de toxina botulinica
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
GB0305989D0 (en) * 2003-03-15 2003-04-23 Delta Biotechnology Ltd Agent
PT2813239T (pt) * 2004-08-04 2017-06-09 Ipsen Biopharm Ltd Composição farmacêutica contendo a neurotoxina botulínica a2
EP1778279B1 (de) * 2004-08-04 2014-12-03 Ipsen Biopharm Limited Pharmazeutische zusammensetzung mit botulinum neurotoxin a2
JP2006045173A (ja) * 2004-08-09 2006-02-16 Hidetoshi Tsuchida 表面修飾血清アルブミン−金属ポルフィリン複合体、およびそれを含有する酸素輸液
WO2007079886A1 (de) 2005-12-22 2007-07-19 Csl Behring Gmbh Oktanoatreduziertes human albumin
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
JP4935242B2 (ja) * 2006-08-24 2012-05-23 ニプロ株式会社 脂肪酸を含有するｓ−ニトロソタンパク質とその製法
EP3170508B1 (de) 2010-06-04 2019-11-13 Wyeth LLC Impstoffformulierungen
JP2016028102A (ja) * 2015-10-21 2016-02-25 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
CN106963942A (zh) * 2016-01-13 2017-07-21 华北制药集团新药研究开发有限责任公司 重组人血白蛋白的液体制剂
US20190142748A1 (en) * 2016-05-26 2019-05-16 Zhuhai Beihai Biotech Co., Ltd. Formulations of chlorambucil
AU2018233184B2 (en) 2017-03-16 2022-06-16 Evolve Biologics Inc. Method for purification of albumin
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
MX2023007767A (es) 2020-12-28 2023-07-07 Davol Inc Materiales hemostaticos secos en polvo reactivos que comprenden una proteina y un agente de entrelazado a base de polietilenglicol modificado multifuncional.
CN114544926A (zh) * 2021-12-02 2022-05-27 浙江鑫科医疗科技有限公司 一种血清蛋白稳定剂
CN118652320B (zh) * 2024-08-16 2024-11-05 通化安睿特生物制药股份有限公司 一种速溶重组人白蛋白冻干的制备方法及其应用
CN118681001B (zh) * 2024-08-19 2024-12-06 通化安睿特生物制药股份有限公司 一种含人白蛋白和葡萄糖的透析液及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4314997A (en) * 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
DE3173208D1 (en) * 1980-10-06 1986-01-23 Edward Shanbrom Method of reducing undesirable activities of biological and pharmaceutical products
US4585654A (en) * 1983-04-29 1986-04-29 Armour Pharmaceutical Co. Process for pasteurizing fibronectin
CA1213827A (en) * 1983-04-29 1986-11-12 Ricardo H. Landaburu Process for pasteurizing fibronectin
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
EP0445108A1 (de) * 1986-03-10 1991-09-11 RUBINSTEIN, Alan I. Verfahren zur behandlung von gammaglobulin

Also Published As

Publication number Publication date
DE68907124T2 (de) 1993-11-04
DE68907124T3 (de) 2005-10-06
AU617451B2 (en) 1991-11-28
EP0341103B2 (de) 2003-08-13
FR2630115A1 (fr) 1989-10-20
JP2970911B2 (ja) 1999-11-02
EP0341103B1 (de) 1993-06-16
ES2055120T3 (es) 1994-08-16
JPH01311027A (ja) 1989-12-15
AU3275689A (en) 1989-10-19
CA1339440C (en) 1997-09-02
US5118794A (en) 1992-06-02
FR2630115B1 (fr) 1994-10-28
EP0341103A1 (de) 1989-11-08
ES2055120T5 (es) 2004-04-16
DE68907124D1 (de) 1993-07-22

Similar Documents

Publication Publication Date Title
ATE90573T1 (de) Verfahren zum stabilisieren von menschlichen albuminloesungen und so erhaltene loesung.
IT8419266A1 (it) Dispositivo per generare calore in tessuti" del corpo umano e procedimento di cenerazione di calore, particolarmente per la cura di tumori
FI962613A0 (fi) Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi
NO903608L (no) Middel for behandling av sterke smertetilstander og fremgangsmaate ved fremstilling derav.
KR890701107A (ko) 알쯔하이머 병 치료용 화합물들
FI913142A0 (fi) Migraenfoerhindrande alkoxipyrimidinderivat.
DK578485A (da) Dihydropyridin-carboxylsyreamider, deres fremstilling og anvendelse i laegemidler
DE3869230D1 (de) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin.
DE68904462D1 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelial-gewebekrankheiten.
DE69024382D1 (de) Fledermausspeichel-Plasminogenaktivator vPA-alpha 1
ATE117898T1 (de) Verfahren und mittel zur präventiven behandlung von chirurgischen adhäsionen.
RU96115137A (ru) Применение диметикона для лечения афт и стоматита
DK0483614T3 (da) Anvendelse af aminosyrer til beskyttelse af og metabolisk restitution af iskæmisk hjertevæv
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
DE58902451D1 (de) (s)-emopamil zur anwendung bei der behandlung von migraene.
ZA888090B (en) Agents for treating high blood pressure and cardiac insufficiency
GR3000751T3 (en) Tpa-containing medical composition and use thereof
ES2077698T3 (es) Agente terapeutico para la gangrena diabetica.
PT91571A (pt) Verfahren fuer die herstellung von phyto und zoosterole und deren derivate mit verbesserter wasseroeslichkeit
DE3776662D1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
ATE316373T1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn
DE3778858D1 (de) 17-benzylspartein-derivate enthaltende positiv inotrop wirksame pharmazeutische zubereitungen.
ES2056804T3 (es) Utilizacion de proteina reguladora procedente de foliculos para la elaboracion de un agente terapeutico para el tratamiento del neoplasma de origen gonadal.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0341103

Country of ref document: EP

EELA Cancelled due to lapse of time